Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial)
Vincenzo AdamoMedical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology University of Messina, MessinaGiuseppina Rosaria Rita RicciardiMedical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology, University of Messina, MessinaVeronica FranchinaMedical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology, University of Messina, MessinaGiuseppa FerraroMedical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology, University of Messina, MessinaMelania CarusoMedical Oncology Unit, Humanitas Catania, CataniaGiuseppe BronteSection of Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, PalermoGiuseppe Luigi BannaDivision of Medical Oncology, Cannizzaro Hospital, CataniaPietro SpadaroA. SavarinoServizio di Oncologia PO Canicattì, CanicattìCalogero IaconoHector Josè Soto ParraMedical Oncology, University Hospital Policlinico, Vittorio Emanuele, CataniaMassimiliano SpadaSan Raffaele Giglio, CefalùValentina SafinaLivio BlasiFilippo ZerilliAngela PrestifilippoCarmelo Giannitto-GiorgioDavide AlberioLorenzo CottiniAnna RussoMedical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo
2015en
Ochiq kirishBronza
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos0 ta foydalanilgan manba